The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Radiology advocates on Monday said they were "deeply disappointed" with the decision while emphasizing it is still early in the process. 

UPDATED: “These high numbers highlight the disconnect between the two sides as they debate what constitutes a reasonable payment for OON services,” experts write in Health Affairs. 

“Just as medicine has its own language, so does business," two surgeons explained in a new editorial. 

An exclusive interview with Hal Andrews, President and CEO of Trilliant Health, on the topic of price transparency and how regulators and companies can contain costs for patients. 

The new name will be familiar to anyone who knows the history of Medtronic's diabetes business.

The country’s largest insurer launched its Designated Diagnostic Provider program in 2022, steering beneficiaries to imaging centers that meet quality and efficiency requirements. 

“Unlike [prior authorization], this model does not delay patient care and does not hold members liable to pay for unneeded exams,” writes radiologist Mark Hiatt, MD, MBA.